Asset Details
Do you wish to reserve the book?
Temperature-Dependent Viral Pathogenicity: Implications for Attenuation of Viral Vaccines
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Temperature-Dependent Viral Pathogenicity: Implications for Attenuation of Viral Vaccines
Do you wish to request the book?
Temperature-Dependent Viral Pathogenicity: Implications for Attenuation of Viral Vaccines
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Temperature-Dependent Viral Pathogenicity: Implications for Attenuation of Viral Vaccines
2025
Overview
This review highlights the role of temperature sensitivity, a common feature of attenuated virus vaccines, in mediating attenuation. Viral attenuation mechanisms were analyzed by comparing vaccine characteristics and genes with those of wild-type viruses. Development of varicella vaccines, particularly their attenuation and immunogenicity in immunocompromised children, provided key insights into these mechanisms. Temperature sensitivity leads to smaller viral microlesion formation than wild-type virus by impaired viral replication before recognition by the innate immune system, eliciting protective immunity without causing clinical symptoms. Vaccine candidates were selected based on their attenuation in humans and replication ability for mass production, with impaired growth and temperature sensitivity as common characteristics among many vaccines. Temperature-sensitive rhinoviruses replicate in the nasal mucosa at 33 °C but not in the lungs at 37 °C, demonstrating in vitro and in vivo temperature sensitivity. Similarly, vaccine-induced immunity arises from viral microlesions caused by impaired growth of temperature-sensitive strains; however, these lesions remain small and result in attenuated clinical symptoms. Because of this impaired growth, higher inoculation doses than those of wild-type strains are required to establish infection and elicit immunity. Therefore, clinical attenuation results from impaired viral replication due to temperature sensitivity, yet it induces protective immune responses.
Publisher
MDPI AG,Multidisciplinary Digital Publishing Institute (MDPI)
